Clinical Trial

Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 8, 2026 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, double-blinded, controlled Phase I study of new process CMAB015 administered by subcutaneous injection. This study will characterize the pharmacokinetic, safety and immunogenicity of new process CMAB015 versus Cosentyx（Secukinumab ） in healthy male subjects after a single dose.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-19.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-05-05
Trial Details
NCT Number NCT07254325
Lead Sponsor Taizhou Mabtech Pharmaceutical Co.,Ltd
Conditions Psoriasis
Enrollment 114 participants
Start Date 2025-12-15
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-08